|1.||Linehan, W Marston: 1 article (01/2011)|
|2.||Woldemichael, Girma M: 1 article (01/2011)|
|3.||Turbyville, Thomas J: 1 article (01/2011)|
|4.||McMahon, James B: 1 article (01/2011)|
|5.||Samusenko, Alexei V: 1 article (02/2004)|
|6.||Preobrazhenskaya, Maria N: 1 article (02/2004)|
|7.||Simonova, Valeria S: 1 article (02/2004)|
|8.||Shtil, Alexander A: 1 article (02/2004)|
|9.||Olsufyeva, Eugenia N: 1 article (02/2004)|
|10.||Tevyashova, Anna N: 1 article (02/2004)|
|1.||Sarcoma (Soft Tissue Sarcoma)
12/01/1977 - "Phase I clinical study of carminomycin: its activity against soft tissue sarcomas."
11/01/1980 - "[Changes in the T- and B-lymphocyte ratio in bone sarcoma patients before and after carminomycin treatment]."
07/01/1976 - "A total of 39 patients with sarcoma of the soft tissues were treated with carminomycin administered intravenously in doses of 10-15 mg twice a week, the total dose being 60-70 mg. The intervals between the courses were 1 month. "
07/01/1976 - "[Therapeutic use of carminomycin in soft tissue sarcomas]."
10/01/1977 - "[Carminomycin in drug combination in breast cancer and soft tissue sarcomas]."
09/01/1977 - "It was shown that karminomycin was more effective in the studied leukemia strains when it was used in the doses with equivalent toxicity. "
08/01/1977 - "The results of the trials showed that karminomycin had a definite therapeutic activity in treatment of acute myeloblast leukemia at various stages of the process. "
01/01/1985 - "A comparative quantitative investigation of colony-forming ability of mouse bone marrow hemopoietic stem cells in the case of ordinary leukemia variant (P-388) and carminomycin-resistant variant (P-388/k) was carried out. "
01/01/1985 - "Phase I-II evaluation of carminomycin in adults with acute leukemia."
01/01/1984 - "In the case of La leukemia the killing of CFUs by carminomycin was the highest as compared with P-388 leukemia."
|3.||Non-Hodgkin Lymphoma (Lymphosarcoma)
02/01/1983 - "When CCH was administered intravenously to mice with lymphosarcoma LIO-1, the antitumor effect selectivity of it was practically equal to that of carminomycin. "
02/01/1982 - "BOC hydrazone and MP imine of carminomycin had a significant antiblastomic activity against lymphosarcoma LIO-1. "
04/01/1981 - "The molar ratios of carminomycin and BSA were 8:1, 4:1, and 2:1. The antitumor effect of the preparations was studied on the models of mouse transplantable lymphosarcoma LIO equal 1 and ascitic forms of mouse lymphadenosis NK/Ly in vivo and in vitro. "
04/01/1978 - "Karminazon had a lower selective antitumor activity with respect to lymphosarcoma than karminomycin."
04/01/1978 - "In its intravenous use in the treatment of mice with lymphosarcoma L10-1 karminazon was less toxic and had lower antitumor activity than karminomycin. "
11/01/2002 - "Dammar-24-ene-3 alpha 2 beta,17 alpha,20(S)-tetraol (compound IV) is cytotoxic for the Ehrlich ascite carcinoma cells and this effect is additive to cytotoxic activity of anthracycline antibiotic carminomycin in vitro. "
02/01/2004 - "These novel derivatives 10 and 12 were less toxic than carminomycin or 14-hydroxycarminomycin for leukemia (K562) and breast carcinoma (MCF-7) cells. "
04/01/1981 - "[Effect of carminomycin on the structural integrity, primary susceptibility to radiation damage and the postradiation repair of the cellular DNA-membrane complex in Ehrlich's ascitic carcinoma]."
04/01/1980 - "[Action of carminomycin on the structural integrity, primary damage susceptibility and postradiation regeneration of the DNA from Erhlich's ascitic carcinoma]."
01/01/1980 - "mammary carcinoma 1142A, Lewis lung carcinoma, metastatic model of the mammary carcinoma 1142A--a combined treatment consisting of vincristine--cyclophosphamide--metrotrexate--5-fluorouracil is superior to a combined treatment with carminomycin--dibromodulcitol. "
01/01/1986 - "The immunological status was investigated in 40 patients with chondrosarcoma of clinical stages II and III. The radical operation was made in 40 patients, the polychemotherapy was applied to 10 of them in the early period and 3,6 and 12 months after the operation (sarcolysin, vincristine, carminomycin in generally accepted doses). "
07/01/1978 - "[Case of the successful use of carminomycin in combination with cyclophosphane and vincristine in treating ectopic chondrosarcoma of rare localization in a 5-month-old infant]."
07/01/1976 - "When used alone or in combination with vincristin or cyclophosphan carminomycin proved to be effective in treatment of sarcoma of the soft tissues (liposarcoma, synovial sarcoma), chondrosarcoma and reticulosarcoma."
|1.||Drug Therapy (Chemotherapy)
|2.||Combination Drug Therapy (Combination Chemotherapy)
|3.||Transplantation (Transplant Recipients)